Search Results

You are looking at 301 - 310 of 2,881 items for :

  • Refine by Access: All x
Clear All
Full access

Strategy for Incorporating Molecular and Cytogenetic Markers into Acute Myeloid Leukemia Therapy

Mark G. Frattini and Peter G. Maslak

Edited by Kerrin G. Robinson

transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders . Blood 2007

Full access

Oncology Practice Guidelines: Do They Work?

Rodger J. Winn

, multidisciplinary management and outcome of treatment for soft tissue sarcomas . Ann Oncol 2004 ; 15 : 307 – 315 . 17 National Health and Medical Research Council . Psychosocial clinical practice guidelines . Information, support and counseling for

Full access

Helping Cancer Survivors Return to Work

Presented by: Amye J. Tevaarwerk

manipulate tools at work). What Are the Consequences? These limitations can lead to a variety of outcomes, including increased struggle but no decrease in productivity, employment instability (eg, change in job or employer), underemployment (ie

Full access

Role of Repeat Resection in Non–Muscle-Invasive Bladder Cancer

Harry W. Herr

variable affecting outcomes of NMIBC is pathologic evaluation of tumor specimens. Although pathologists may differ in their interpretation, they can only assess what they are given by the urologist. As an example, one study found that muscularis propria was

Full access

Strategies for the Treatment of Acute Promyelocytic Leukemia

Olga Frankfurt and Martin S. Tallman

rate limiting mutation . Leukemia 2000 ; 14 : 722 – 726 . 23. Pulsoni A Pagano L Lo Coco F . Clinicobiological features and outcome of acute promyelocytic leukemia occurring as a second tumor: the GIMEMA experience . Blood 2002 ; 100

Full access

Early Antibiotic Discontinuation or De-escalation in High-Risk Patients With AML With Febrile Neutropenia and Prolonged Neutropenia

William Alegria, Bernard L. Marini, Kevin Sellery Gregg, Dale Lee Bixby, Anthony Perissinotti, and Jerod Nagel

-HCTs). 8 – 10 A recent randomized, open-label, multicenter study in patients with FN without a documented infectious source showed an overall reduction in empirical antimicrobial therapy (EAT)–free days without adversely affecting clinical outcomes. 9 It

Full access

Expanding the Use of Nephron-Sparing Surgery for Wilms Tumor

Christopher J. Long, Sameer Mittal, and Thomas F. Kolon

outcomes for PN. Several studies have examined outcomes of NSS for BWT, while a recent systematic review summarized this diverse group. 5 The review analyzed 66 studies, with 4,002 patients undergoing either RN or PN. Although limited by the quality of

Full access

Radiotherapy in the Multidisciplinary Management of Merkel Cell Carcinoma

Michael D. Green and James A. Hayman

inoperable patients, patients in whom surgery would result in unacceptable functional or cosmetic outcomes, or those who decline surgery may be candidates for definitive RT alone. Radiobiological studies have indicated that the disease is very radiosensitive

Full access

Healthcare Access Dimensions and Guideline-Concordant Ovarian Cancer Treatment: SEER-Medicare Analysis of the ORCHiD Study

Mary Katherine Montes de Oca, Lauren E. Wilson, Rebecca A. Previs, Anjali Gupta, Ashwini Joshi, Bin Huang, Maria Pisu, Margaret Liang, Kevin C. Ward, Maria J. Schymura, Andrew Berchuck, and Tomi F. Akinyemiju

improved survival outcomes, and lack of concordance with the NCCN Guidelines is an independent predictor of worse survival. 6 , 10 , 11 Some evidence suggests that equal care leads to similar outcomes among Black and White women with advanced OC 12 , 13

Full access

Relapsed/Refractory CLL/SLL: Overcoming Resistance to Covalent BTKi and/or BCL2 Inhibitors

Presented by: Brian T. Hill

In recent years, the treatment landscape for relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has seen significant advancements, ushering in an era of targeted therapies that have transformed patient outcomes